Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase

Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase

Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part of combination therapies, cause severe adverse reactions in about 10%–30% of patients. Dihydropyrimidine dehydrogenase (DPD), a key enzyme in the catabolism of 5-fluorouracil, has been intensively inves...

Full description

Bibliographic Details
Main Authors: Falvella, Felicia Stefania, Caporale, Marta, Cheli, Stefania, Martinetti, Antonia, Berenato, Rosa, Maggi, Claudia, Niger, Monica, Ricchini, Francesca, Bossi, Ilaria, Di Bartolomeo, Maria, Sottotetti, Elisa, Bernardi, Francesca Futura, de Braud, Filippo, Clementi, Emilio, Pietrantonio, Filippo
Format: Online
Language:English
Published: MDPI 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425114/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425114/

Similar Items